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Abstract
It has been reported that blocking Notch signaling in tumor-bearing mice results in abortive angiogenesis and
tumor regression. However, given that Notch signaling influences numerous cellular processes in vivo, a com-
prehensive evaluation of the effect of Notch inactivation on tumor growth would be favorable. In this study, we
inoculated four cancer cell lines in mice with the conditional inactivation of recombination signal-binding protein-Jκ
(RBP-J), which mediates signaling from all four mammalian Notch receptors. We found that whereas three tumors
including hepatocarcinoma, lung cancer, and osteogenic sarcoma grew slower in the RBP-J–deficient mice, at
least a melanoma, B16, grew significantly faster in the RBP-J–deficient mice than in the controls, suggesting that
the RBP-J–deficient hosts could provide permissive cues for tumor growth. All these tumors showed increased
microvessels and up-regulated hypoxia-inducible factor 1α, suggesting that whereas defective angiogenesis re-
sulted in hypoxia, different tumors might grow differentially in the RBP-J–deleted mice. Similarly, increased infil-
tration of Gr1+/Mac1+ cells were noticed in tumors grown in the RBP-J–inactivated mice. Moreover, we found that
when inoculated in the RBP-J knockout hosts, the H22 hepatoma cells had a high frequency of metastasis and
lethality, suggesting that at least for H22, deficiency of environmental Notch signaling favored tumor metastasis.
Our findings suggested that the general blockade of Notch signaling in tumor-bearing mice could lead to defective
angiogenesis in tumors, but depending on tumor cell types, general inhibition of Notch signaling might result in
tumor regression, progression, or metastasis.
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Introduction
Interactions between tumor cells and host environments are critical
for tumor growth and metastasis. Whereas the immune system of
host intends to exclude tumors, tumor cells recruit vessels and growth
factors from host environment to support their own expanding and
metastasis. These environmental elements have been targets for novel
therapies of cancers. More than 30 years ago, Folkman [1] proposed
that solid tumor growth depends on vascular network formation.
Since then, endeavors to intervene tumor angiogenesis have attracted
worldwide attentions and exciting progresses have been made [2,3].
The vascular endothelial growth factor (VEGF), a major proangio-
genic cytokine, was firstly targeted, and anti-VEGF therapies have
indeed improved survival of colorectal, lung, and breast cancer pa-
tients. However, inhibition of neovascularization by anti-VEGF is
not always effective in solid tumor therapy as expected [4]. Thus,
new targets on tumor vascular network formation are badly required.
Abbreviations: RBP-J, recombination signal-binding protein-Jκ; VEGF, vascular endo-
thelial growth factor; HIF, hypoxia-inducible factor
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Notch signaling, one evolutionarily conserved pathway, is instru-
mental in many developmental processes by participating in cell fate
determination during embryonic and postnatal stages. Hitherto, four
Notch receptors (Notch1-4) and five ligands (Jagged1, Jagged2, and
Delta-like ligands (Dll) 1, 3, and 4) have been identified in mammals.
On ligand-receptor binding, Notch intracellular domain is cleaved by
consecutive enzymatic reactions, and Notch intracellular domain sub-
sequently translocates into the nucleus, where it interacts with the
transcription factor C promoter-binding factor 1/recombination signal-
binding protein J/κ (RBP-J). After that, target genes such as Hes family
basic helix-loop-helix members are activated to transcribe [5].
Notch signaling is involved in the regulation of tumor behavior in
multiple dimensions. Notch signaling can directly function as an on-
cogene or a tumor suppressor and influence tumor cell proliferation,
differentiation, apoptosis, and genome instability [6,7]. On the host
side, bulk evidence has shown that Notch signaling is a key regulator
of vascular development in tumors. Notch signaling is critical in angio-
genesis and endothelial cell fate determination both in embryonic
and postnatal development [8,9]. Gene mutations in the Notch
pathway give rise to embryonic lethality caused by defects in vascular
remodeling [10–14]. Supported by conditional knockout strategy, we
have shown that in adult mice, Notch signaling plays a critical role
in the maintenance of homeostasis of normal vasculature by repress-
ing endothelial cell proliferation [15]. It was reported recently that in
tumor-bearing mice, down-regulation of Dll4, one ligand of Notch
receptors, led to retarded tumor growth due to more but functionally
impaired neovascularization, which imposed more severe hypoxia on
tumor cells [16–19]. On the basis of these findings, the Notch sig-
naling has been chosen as a potential intervening target for vessel-
based tumor therapies.
In addition to endothelial cells, Notch signaling regulates cell fate
commitment, proliferation, and apoptosis in the hematopoietic sys-
tem. Therefore, universal intervening of Notch signaling influences
multiple steps in cell differentiation in the immune system and im-
mune responses [20], which is also critical for tumor behaviors. It
has been demonstrated that Notch signaling determines cell fate de-
cisions at the developmental checkpoints of T cells versus B cells [21],
αβ-T cells versus γδ-T cells [22], follicular B cells versus marginal
zone B cells [23], and so on. Notch signaling may also regulate im-
mune responses by modulating dendritic cells [24], nature killer cells,
and T cell proliferation [25]. More importantly, it has been proved
that Dll4, which is believed to be specifically involved in the vascular
system, also regulates cell fate determinations in the immune system
[20]. Therefore, it would be advantageous to know the comprehen-
sive effects of universal Notch signal inhibition in host environment
for tumor growth and metastasis.
In this study, we used a mouse model in which RBP-J [23], the
common transcription factor of all four Notch receptors, was condi-
tionally inactivated. We found that tumors inoculated in the RBP-J–
inactivated mice showed differential features: hepatocarcinoma, lung
cancer, and osteosarcoma grew slower but melanoma grew signifi-
cantly faster than inoculated in normal environment, in contrast with
previous reports. All inoculated tumors had increased neovasculari-
zation and decreased perfusion as shown by up-regulated hypoxia-
inducible factor (HIF) 1α expression and by increased infiltration
of immunorepressive Gr1+/Mac1+ immature monocytes. Moreover,
hepatocarcinoma showed increased metastasis. These results strongly
suggested that the output of Notch-targeted cancer therapy might
depend on cancer cell types.
Materials and Methods
Mice
Mice were maintained in a specific pathogen-free condition. The
RBP-J–floxed (RBP-Jf ) mice were as described [26] and were crossed
with the Mx-Cre transgenic mice to get the RBP-Jf/f-MxCre and
RBP-J+/f-MxCre (as controls) mice (hence, referred as RBP-J−/− and
RBP-J+/−, respectively). Mice were genotyped by polymerase chain re-
action [24]. Four-week-old mice were injected intraperitoneally with
300 μg/100 μl poly(I)-poly(C) (Sigma, St. Louis, MO) for four times
at 2-day intervals and were then injected with the same dosage of poly
(I)-poly(C) for another set of four times at 1-week intervals (eight in-
jections in total). All animal experiments were approved by the Fourth
Military Medical University.
Cell Culture
Lewis lung carcinoma (LLC), mouse S180 sarcoma (S180), mouse
H22 hepatocarcinoma (H22), and mouse melanoma (B16) cell lines
were gifts from Dr. C.H. Shi. All the tumor cell lines were main-
tained in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 50 IU/ml penicillin, and 50 μg/ml strep-
tomycin sulfate.
Tumor-Bearing Mouse Models
Tumor cells (5 × 106) were injected subcutaneously into the RBP-J
knockout and the control mice. Seven days after the initial inocula-
tion, tumor growth was monitored every 2 days by measuring tumor
length (L) and short (S ) with a sliding caliper. Tumor size was calcu-
lated as L × S2 × 0.51.
Two weeks after the initial inoculation, weight of tumor-bearing
mice was recorded before being killed. Tumors were excised and
the weight was measured. Tumor weight index was calculated as
the ratio of tumor weight to body weight.
FACS Analysis
Cells were collected from minced tumor tissues. After filtrating
through a nylon filter, cells were resuspended with phosphate-buffered
saline containing 2% fetal bovine serum and 0.05% NaN3 and
were counted. Cells (3-5 × 105) were stained with PE–anti-Mac1
(M/10) and fluorescein isothiocyanate–anti-Gr1 (M815214) anti-
bodies (both from Pharmingen, San Diego, CA) at 4°C for 30 minutes
before being analyzed using a FACSCalibur (BD Immunocytometry
System, San Jose, CA). Dead cells were excluded by propidium iodide
gating. Data were analyzed using the CellQuest software.
Histology and Immunohistochemistry
Tissues were fixed in 4% paraformaldehyde, embedded in paraffin,
sectioned at 10 μm thickness, and stained with hematoxylin and eosin
by standard methods. Immunohistochemistry was performed by stan-
dard procedures, with rat antimouse CD31 (1:500 dilution; Chemicon
International) or rabbit antimouse HIF1α antibody (1:200 dilution;
Chemicon International, Temecula, CA) as the primary antibody. Sec-
ondary antibodies included horseradish peroxidase–conjugated goat
antirat IgG or antirabbit IgG (Boster BioTec, Wuhan, China). Sam-
ples were developed using standard DAB reagents and were observed
under a microscope. To evaluate the density of microvessels, micro-
vessels were counted by different technicians based on “hot field,” which
showed the most concentrated vessel regions. For the quantification,
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pictures were captured and then pixels were determined by Image-Pro
Plus 5.1 software (MediaCybernetics Inc., Bethesda, MD).
Dorsal Air Sac Assay
Dorsal air sac assay was carried out as described [27]. In brief, sub-
cutaneous dorsal air sac was created in mice by injecting 2.5 ml of
air. Chambers were produced by covering both sides of a Millipore
ring with Millipore filters (0.45 μm) and were filled with a suspen-
sion of 1 × 107 tumor cells in 0.15 ml of phosphate-buffered saline.
Three days later, the chambers were implanted into the dorsal air
sac. Five days after the implantation, the local skin was cut open,
and tumor angiogenesis was assessed under a microscope.
Statistics
The significance of the difference between groups was statistically
analyzed by SPSS 11.0 program (SPSS, Inc., Chicago, IL) using Stu-
dent’s t test.
Results
Differential Tumor Cell Growth in RBP-J Knockout Mice
Although it has been reported that blocking Notch signaling in
tumor-bearing mice induces tumor regression owing to abortive angio-
genesis, the whole scenario of the effects of Notch signal inactiva-
tion on tumor growth has not been fully investigated. To explore
this, we used the RBP-J conditional deletion mouse model [26].
In the adult RBP-Jf/f–MxCre mice, injection of the α-interferon in-
ducer poly(I)-poly(C) induced deletion of the DNA-binding domain
of RBP-J. The deletion was almost complete in hematopoietic cells
and endothelial cells [15,26].
We inoculated subcutaneously four mouse tumor cell lines, in-
cluding LLC, H22, S180, and B16, into the RBP-J–inactivated and
the control mice. Both S180 and H22 expressed Notch4 and Dll4,
whereas LLC expressed Notch2 and B16 expressed Notch1, as de-
tected by reverse transcription–polymerase chain reaction (data not
shown). On day 15 after the inoculation of 5 × 106 tumor cells, com-
pared with tumors inoculated in the control mice, LLC, H22, and
S180 tumors in the RBP-J−/− mice were significantly smaller (Fig-
ure 1A). Tumor weight index also indicated that these three tumors
were significantly smaller in the RBP-J−/− mice than in the controls
(Figure 1B). We monitored the dynamic increase of tumor volumes
from the seventh day after the injection of tumor cells. In the case
of LLC, H22, and S180, tumor volumes in the RBP-J−/− mice were
significantly smaller than those in the control mice, and the differences
remained even when the tumors grew larger (Figure 1C). This was in
agreement with previous reports showing that interruption of Notch
signaling in mice retarded tumor growth, most likely attributed to de-
fective angiogenesis [16–19].
In contrary to LLC, H22, and S180 tumors, the size of B16 mela-
noma grown in the RBP-J–deleted mice was significantly larger than
in the control mice (Figure 1A, lowest panel ). Comparison of tumor
weight index on day 15 after inoculation also indicated that the B16
tumors in the RBP-J−/− mice were significantly larger than those in
the control mice (Figure 1B, lowest panel ). Tumor growth curve
showed that the B16 grew significantly faster in the RBP-J−/− mice
than in the control mice (Figure 1C , lowest panel ). This suggested that
Figure 1. Tumor growth in the RBP-J−/− and control mice. (A) LLC, H22, S180, and B16 tumor cells (5 × 106) were injected subcuta-
neously into the RBP-J−/− and RBP-J+/− mice. Tumors were dissected 15 days after the inoculation and were photographed; represen-
tative tumors were shown. (B) Tumor weight index (ratio of tumor weight–body weight) was compared on day 15 after the tumor
inoculation. (C) Tumor volume. Tumor volume was monitored every 2 days from the seventh day after the inoculation, by measuring
tumor length (L) and short (S ) with a sliding caliper. Tumor volume = L × S2 × 0.51. Bars, means ± SD. *P < .05. n = 3 in LLC; n = 3 in
S180; n = 5 in H22; and n = 5 in B16.
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in a Notch signal–deficient host, the growth of tumors might be dif-
ferent, depending on tumor cell types.
Defective Angiogenesis in Tumors Grown in the
RBP-J–Inactivated Mice Did Not Necessarily
Lead to Tumor Regression
Abortive formation of neovasculature and consequent poor perfu-
sion in solid tumors were considered as the reasons of tumor regression
in the absence of Notch signaling [16–19]. We therefore examined
microvessels in tumors inoculated in the RBP-J knockout and the con-
trol mice. Immunohistochemical staining of vasculature with anti-
CD31 antibody showed that the microvessel density of tumors grown
in the RBP-J–deleted mice increased significantly in all four types of
tumors compared with the controls (Figure 2A, upper panel ). Quanti-
fication of microvessel counts also indicated that the amount of micro-
vessels in tumors grown in the RBP-J–deficient mice were significantly
higher than those in tumors in the control mice (Figure 2B).
We next evaluated tissue hypoxia in tumors by the examination of
HIF1α expression using immunohistochemistry. The expression of
HIF1α was up-regulated in tumors grown in the RBP-J–deficient
Figure 2. Density of microvessels and hypoxia in tumor tissues. (A) Tumors from the RBP-J−/− and control mice were sectioned at
10 μm and were stained for CD31 and HIF1α by immunohistochemistry. (B) Microvessels in (A; upper panel) were counted under a
microscope, and microvessel densities (microvessels per field) were compared. (C) HIF1α-positive signals in (A; lower panel) were quan-
tified using Image-Pro Plus 5.1 and were compared for statistical significance. Bars, means ± SD. *P < .05, **P < .01; n = 5.
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mice (Figure 2A, lower panel ). Quantification analysis also indicated
that the hypoxia areas of tumors grown in the RBP-J–deficient mice
were significantly larger than those in tumors in the control mice
(Figure 2C ), suggesting augmented hypoxia in all four types of tu-
mors, although they showed different growth (Figure 1). These data
indicated that in the RBP-J–deleted mice, defective vascular network
formation might lead to poor perfusion and tissue hypoxia, but this
did not have to result in tumor regression.
Increased Infiltration of Gr1+/Mac1+ Cells in Tumors Grown
in the RBP-J −/− Mice
Notch signaling controls multiple steps of hematopoiesis in addition
to angiogenesis [20]. Recent reports have shown that Gr1+/Mac1+ cells
are immunorepressive, promoting solid tumor growth [28], and medi-
ating resistance to anti-VEGF therapy [29], so we examined this popu-
lation of cells in tumors inoculated in the RBP-J–mutated and the
control mice. FACS analysis showed that Gr1+/Mac1+ cell infiltration
was significantly higher in tumors grown in the RBP-J–deleted mice
than those grown in the control mice, both in cell proportion (Fig-
ure 3A) and in absolute cell number (Figure 3B) per tumor. T cells,
B cells, natural killer cells, and dendritic cells infiltrated equally in tu-
mors grown in the RBP-J knockout and the control mice (data not
shown). These results suggested that increased Gr1+/Mac1+ cell infil-
tration in tumors in the RBP-J–disrupted mice might not account for
differential growth of tumors inoculated in these mice.
RBP-J Deletion in Hosts Increased Tumor Metastasis of
H22 Hepatocarcinoma
In our tumor-bearing experiments, we found that H22 hepato-
carcinoma had a higher lethality when inoculated in the RBP-J–
deficient mice (Figure 4A). Mouse autopsy showed that there was
a higher frequency of metastases (3/7) in the liver and abdominal
cavity of the RBP-J–deficient mice inoculated with H22 cells (Fig-
ure 4B). Because the density of microvessels in H22 tumors grown in
the RBP-J–deficient mice was higher than that of tumors grown in
the controls and abnormal microvessel structure could be a risk factor
of increased tumor metastasis, we further examined typical general
tumor angiogenesis in H22 tumors using the dorsal air sac analysis.
As shown in Figure 4, C and D, more typical general tumor vessels
formed in H22 hepatocarcinoma grown in the RBP-J−/− mice, com-
pared with tumors grown in the control mice. These data suggested
that the systemic inhibition of the Notch pathway could facilitate
metastasis in some cancers.
Discussion
Antiangiogenesis has been considered as a novel strategy for the ther-
apy for malignant solid tumors, because solid tumor growth depends
on vascular network formation, as proposed by Folkman [1] more
than 30 years ago. Indeed, colorectal cancers, lung cancers, and breast
cancers are sensitive to Avastin [30], a monoclonal antibody against
VEGF. However, other solid tumors, such as lymphoma, appear
Figure 3. Infiltration of Gr1+/Mac1+ cells in tumors grown in the RBP-J knockout and control mice. (A) FACS analysis. Tumors grown
in the RBP-J−/− and control mice were dissected and were minced to obtain single-cell suspensions. FACS was carried out using PE–
anti-Mac1 and fluorescein isothiocyanate–anti-Gr1. Pictures represent one set of three to five independent experiments. (B) The number
of Gr1+/Mac1+ cells in tumors was calculated based on FACS shown in (A). Bars, means ± SD. *P < .05. n = 3 in LLC; n = 3 in S180;
n = 5 in H22; and n = 5 in B16, respectively.
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refractory to the same therapy [29]. Thus, new targets for antiangio-
genic therapy for tumors are desired. Notch signaling is essential for
normal angiogenesis and the maintenance of vascular homeostasis
[8,9,15]. Recently, Notch signaling has been chosen as a therapeutic
target for tumors because the blockade of Dll4, one of the Notch
ligands, induces defective angiogenesis leading to tumor regression in
many tumor cell types, including human colon cancer (HM7), human
colon adenocarcinoma (Colo205), human non–small cell lung carci-
noma (Calu6), human breast carcinoma (MDA-MB-435), human
lung adenocarcinoma (MV-522), human fibrosarcoma (HT1080),
and mouse myelomonocytic tumor (WEHI3) and rat glioma (C6)
[17,18]. However, although the consequence of the Dll4 intervention
is mainly restricted to the vascular system [18], Dll4 has been shown
expressed in a large spectrum of cell types and functions in other sys-
tems than only in vasculature [20–26]. It is therefore essential to inves-
tigate the comprehensive effects of Notch signal blockade on tumor
growth before those Notch-targeted therapies could be adopted in
clinics. Because of the functional redundancy among different ligands
or receptors in the Notch pathway [20], in this study, we used the
mouse model that bears a conditional inactivation of RBP-J [26], the
common transcription factor of all four Notch receptors in mammals.
We found that not all types of tumors adapted in this study re-
gressed when inoculated in the RBP-J knockout mice. Indeed, sev-
eral types of tumors, such as those tested in previous studies [17,18]
and LLC, H22, and S180 in this study, were retarded in an envi-
ronment deprived of Notch signaling. However, the B16 melanoma
grew faster when inoculated in the RBP-J knockout mice. Abortive
formation of neovasculature and, consequently, poor perfusion in
solid tumors has been considered as reasons of tumor regression in
the absence of Notch signaling [16–19]. In this study, increased an-
giogenesis (anti-CD31 staining) and decreased tissue perfusion (anti-
HIF1α staining) were prominent in all tumors grown in the RBP-J
knockout mice, suggesting that defective angiogenesis resulting from
Notch signal intervention might not have to result in tumor regres-
sion in all tumor cell types.
Antitumor immune responses might be another issue that must
be considered because the Notch pathway has been demonstrated
as one of the major players in controlling the development and func-
tion of the immune system. In tumors grown in the RBP-J knockout
mice, the most significant change was the higher amount of infil-
trated Gr1+/Mac1+ cells in tumor tissues. Infiltration of Gr1+/Mac1+
cells in solid tumors was reported more than 20 years ago [31]. Re-
cently, it was found that Gr1+/Mac1+ cells play a role to promote
tumor growth and mediate refractoriness to anti-VEGF therapy [29],
possibly by resulting in the down-regulated expression of MHC II
[28]. In the RBP-J−/− mice, Gr1+/Mac1+ cells in peripheral lymphoid
organs increased (unpublished results). However, we did not find sig-
nificant difference in Gr-1+/Mac-1+ cell infiltration among different
tumors inoculated in the RBP-J knockout mice, suggesting that this
might not be the reason of differential growth of these tumors. How-
ever, the fact that systemically blockade of Notch pathway gives rise to
a significantly increase of Gr1+/Mac1+ cells might still be an important
consideration for the development of Notch-based tumor therapies.
In addition to the vascular and immune systems, tumor-bearing
host might provide other signals influencing tumor growth. For exam-
ple, endothelial cells could promote liver development and regenera-
tion in addition to functions in vascular formation. This is achieved
by VEGF signaling through VEGFR1, which ultimately leads to the
secretion of interleukin 6 and hepatocyte growth factor by endothelial
cells to support the proliferation of hepatocytes [32]. Endothelial cells
invading into solid tumors might also produce cytokines and other fac-
tors that favor tumor growth. Inactivation of Notch signaling might
Figure 4. RBP-J−/− environment promoted metastasis of H22 hepatocarcinoma. (A) Survival of mice subcutaneously inoculated with
H22 hepatocarcinoma cells. (B) Liver metastasis in the RBP-J−/− mice subcutaneously inoculated with H22 cells. Seven pairs of the
RBP−/− and RBP+/− mice were inoculated with H22 tumor cells. Liver metastasis was examined 15 days later after tumor injection. (C)
Dorsal air sac assays of tumor angiogenesis. Typical tumor vasculatures were shown in the insets. (D) Quantification of newly formed
tumor vessels. Microvessels with the characteristics of tumor vasculature were counted under a microscope and were compared. Bars,
means ± SD. *P < .05, n = 3.
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influence this process and lead to differential growth of tumors in the
RBP-J deficient mice. In this study, it is possible that these are the
reasons why tumors grow slower in LLC, H22, and S180, as suggested
in prior studies, and that additional, specific factors are induced only in
melanomas causing increased growth. Similarly, specific factors in-
duced only in hepatocarcinomas could induce metastasis.
Although Notch signaling was reported to be involved in metasta-
sis of prostate cancer cell [33] and pancreas cancer cells [34] in vitro,
little information in detail was obtained about tumor metastasis once
the Notch pathway was blocked in tumor-bearing hosts in vivo.
Tumor metastasis through blood vessels involves the disruption of
local microvessels, entering the blood stream, and homing of cancer
cells in the target tissues [35]. We have found that newly formed vas-
cular networks in the absence of Notch signaling are leaky [15]. Our
dorsal air sac assay showed that more general typical tumor vessels
formed in H22 tumors grown in the RBP-J−/− mice, which might
increase the possibility of metastasis.
Solid tumor growth and metastasis are complicated processes in-
volving local growth environment and immune responses in addition
to tumor-intrinsic factors. The Notch signaling pathway may influ-
ence all these aspects. Our findings suggested that the general block-
ade of Notch signaling in tumor-bearing mice could lead to defective
angiogenesis in tumors, but depending on tumor cell types, general
inhibition of Notch signaling might result in tumor repression, pro-
gression, or metastasis.
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